Madrigal Pharmaceuticals
MDGL · Nasdaq · United States
Share price · MDGL
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MDGL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026-5.7%
- 9 Nov 2026+8.3%
- 3 Nov 2026-8.1%
- 26 Aug 2026+5.2%
Nothing announced by MDGL that day or the session before.
- 30 Jul 2026-9.8%
- 3 Jun 2026+7.8%
- 26 Mar 2026+12.3%
Nothing announced by MDGL that day or the session before.
- 19 Feb 2026-11.1%
- 9 Jan 2026-7.6%
Nothing announced by MDGL that day or the session before.
- 6 Jan 2026-5.2%
Nothing announced by MDGL that day or the session before.
Share of unusual movement by asset
For each asset, the share of MDGL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
Resmetirom(Rezdiffra) | Approved | Thyroid hormone receptor-betaSmall molecule | MASH / NASH |
| Phase 2 | Diacylglycerol acyltransferase 2 (DGAT2)Small molecule | MASH / NASH | |
ARO-PNPLA3No recent activity | Phase 1 | PNPLA3RNA / oligonucleotide | MASH / NASH |
| Preclinical / Unstaged | GLP-1 receptorSmall molecule | MASH / NASH |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (1)
March 2027 (1)
What to watch
2028 (2)
2029 (1)
July 2029 (1)
What to watch
Financial reports
Quarterly & interim (19)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $431M | $72M | $515M+ $446M short-term inv. | —$121M operating cash flow | report ↗ |
View 18 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $364M | $91M | $293M+ $546M short-term inv. | $58M$23M operating cash flow | report ↗ |
| 2026-Q1 | $311M | $109M | $232M+ $586M short-term inv. | $94M-$167M operating cash flow | report ↗ |
| 2025-Q3 | $287M | $174M | $301M+ $814M short-term inv. | $114M$80M operating cash flow | report ↗ |
| 2025-Q2 | $213M | $54M | $191M+ $611M short-term inv. | $42M-$47M operating cash flow | report ↗ |
| 2025-Q1 | $137M | $44M | $189M+ $659M short-term inv. | $73M-$89M operating cash flow | report ↗ |
| 2024-Q3 | $62M | $69M | $238M+ $766M short-term inv. | $107M-$67M operating cash flow | report ↗ |
| 2024-Q2 | $15M | $71M | $500M+ $563M short-term inv. | $152M-$135M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $71M | $623M+ $437M short-term inv. | $148M-$149M operating cash flow | report ↗ |
| 2023-Q4 | — | $71M | $100M+ $534M short-term inv. | $112M-$80M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $71M | $62M+ $170M short-term inv. | $99M-$85M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $69M | $77M+ $221M short-term inv. | $86M-$75M operating cash flow | report ↗ |
| 2023-Q1 | — | $62M | $113M+ $216M short-term inv. | $77M-$84M operating cash flow | report ↗ |
| 2022-Q4 | — | $71M | $332M+ $27M short-term inv. | $86M-$59M operating cash flow | report ↗ |
| 2022-Q3 | — | $68M | $59M+ $94M short-term inv. | $81M-$59M operating cash flow | report ↗ |
| 2022-Q2 | — | $59M | $53M+ $158M short-term inv. | $71M-$57M operating cash flow | report ↗ |
| 2022-Q1 | — | $48M | $42M+ $178M short-term inv. | $58M-$50M operating cash flow | report ↗ |
| 2021-Q4 | — | $53M | $36M+ $234M short-term inv. | $65M-$48M operating cash flow | report ↗ |
| 2021-Q3 | — | $55M | $49M+ $250M short-term inv. | $63M-$46M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $958M | $389M | $204M+ $785M short-term inv. | $72M-$190M operating cash flow | report ↗ |
For fiscal 2025, Madrigal Pharmaceuticals reported revenue of $958.4M, up 432.1% YoY, and R&D spend of $388.53M, up 64.1% YoY. Cash and equivalents stood at $203.78M, with a net loss of $288.28M and a reported quarterly net burn of $288.28M.
During 2025, the company launched Rezdiffra in Germany following European Commission conditional marketing authorization and continued U.S. commercialization. Clinical developments included positive two-year data in compensated MASH cirrhosis from the MAESTRO-NAFLD-1 trial, with MAESTRO-NASH OUTCOMES data expected in 2027 and confirmatory MAESTRO-NASH outcomes data expected in 2028. The company also expanded its pipeline through global license agreements for MGL-2086, ervogastat, and six siRNA programs, and entered a senior secured financing agreement with up to $500.0M in commitments, including an initial term loan of $350.0M funded in July 2025.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $180M | $237M | $105M+ $826M short-term inv. | $116M-$456M operating cash flow | report ↗ |
| 2023-FY | $0 | $272M | $100M+ $534M short-term inv. | $93M-$324M operating cash flow | report ↗ |
| 2022-FY | $0 | $245M | $332M+ $27M short-term inv. | $74M-$225M operating cash flow | report ↗ |
| 2021-FY | — | $205M | $36M+ $234M short-term inv. | $60M-$184M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 5 purchases ($35.0M), 178 sales ($69.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-06 | Kelley Shannon T · General Counsel | Open-market sale | 1,077 | $400.00 | $431K | Form 4 |
| 2026-11-06 | BAKER BROS. ADVISORS LP; Baker Bros. Advisors (GP) LLC; BAKER FELIX; BAKER JULIAN; 667, L.P.; Baker Brothers Life Sciences LP · director; director; director; director; director; director | Open-market purchase | 60,400 | $383.01 | $23.1M | Form 4 |
| 2026-11-06 | BAKER BROS. ADVISORS LP; Baker Bros. Advisors (GP) LLC; BAKER FELIX; BAKER JULIAN; 667, L.P.; Baker Brothers Life Sciences LP · director; director; director; director; director; director | Open-market purchase | 13,740 | $388.29 | $5.3M | Form 4 |
| 2026-11-06 | BAKER BROS. ADVISORS LP; Baker Bros. Advisors (GP) LLC; BAKER FELIX; BAKER JULIAN; 667, L.P.; Baker Brothers Life Sciences LP · director; director; director; director; director; director | Open-market purchase | 2,000 | $396.61 | $793K | Form 4 |
| 2026-11-04 | BAKER BROS. ADVISORS LP; Baker Bros. Advisors (GP) LLC; BAKER FELIX; BAKER JULIAN; 667, L.P.; Baker Brothers Life Sciences LP · director; director; director; director; director; director | Open-market purchase | 5,586 | $366.99 | $2.1M | Form 4 |
| 2026-11-04 | BAKER BROS. ADVISORS LP; Baker Bros. Advisors (GP) LLC; BAKER FELIX; BAKER JULIAN; 667, L.P.; Baker Brothers Life Sciences LP · director; director; director; director; director; director | Open-market purchase | 10,080 | $368.11 | $3.7M | Form 4 |
| 2026-09-11 | Sibold William John · director, President and CEO | Open-market sale | 60 | $533.09 | $32K | Form 4 |
| 2026-09-11 | Sibold William John · director, President and CEO | Open-market sale | 106 | $534.06 | $57K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 375 reporting institutions held 23.8M shares ($12.1B, 102.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 2,141,701 | $1.1B |
| 2 | JANUS HENDERSON GROUP PLC | 2,018,647 | $1.1B |
| 3 | RTW INVESTMENTS, LP | 1,993,687 | $1.0B |
| 4 | Avoro Capital Advisors LLC | 1,818,181 | $951.8M |
| 5 | BlackRock, Inc. | 1,559,965 | $816.6M |
| 6 | PAULSON & CO. INC. | 1,392,188 | $728.8M |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 841,145 | $440.3M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 827,144 | $433.0M |
| 9 | WELLINGTON MANAGEMENT GROUP LLP | 694,958 | $363.8M |
| 10 | STATE STREET CORP | 609,525 | $319.1M |
| 11 | FMR LLC | 511,728 | $267.9M |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 455,870 | $238.7M |
| 13 | CITADEL ADVISORS LLC | 453,843 | $237.6M |
| 14 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 340,519 | $178.3M |
| 15 | Invesco Ltd. | 329,519 | $172.5M |